Wyeth Halts Alzheimer’s Trial, Drops HCV Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
With partner Elan, company halts ACC-001 Phase II trials after report of skin lesions.
You may also be interested in...
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.